Sana Biotechnology (SANA) Total Non-Current Liabilities (2020 - 2026)

Sana Biotechnology has reported Total Non-Current Liabilities for 7 years, with the latest figure at $171.2 million in Q1 2026.

• Quarterly Total Non-Current Liabilities fell 24.58% year-over-year to $171.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $171.2 million (down 24.58% YoY) and the FY2025 annual result came in at $245.4 million, up 1.99% from the prior year.
• Total Non-Current Liabilities retreated to $171.2 million in Q1 2026 per SANA's latest filing, from $245.4 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $259.5 million in Q3 2024 and troughed at $168.2 million in Q4 2023.
• A 5-year average of $224.5 million and a median of $232.2 million in 2025 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities dropped 28.44% in 2022, then jumped 43.07% in 2024.
• Over 5 years, Total Non-Current Liabilities stood at $228.4 million in 2022, then fell by 26.35% to $168.2 million in 2023, then jumped by 43.07% to $240.6 million in 2024, then increased by 1.99% to $245.4 million in 2025, then slumped by 30.26% to $171.2 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $171.2 million, $245.4 million, and $232.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.